Glaukos Corporation vs Merck & Company, Inc. — Stock Comparison

GKOS
Glaukos Corporation
$140.22
▼ 2.40%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 5.8/10

Q·Score Breakdown

5.8
Neutral
Overall
6.7
Neutral
1.1
Quality
6.2
9.2
Health
7
7.4
Growth
6.2
4.2
Valuation
7.2
8.9
Sentiment
7.1
GKOS

Clean balance sheet with low leverage (0.2× debt-to-equity).

currently unprofitable (-34% margin).

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $151.08 (+7.7%)
12 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

GKOS
MRK
Trailing P/E
31.5×
293.1×
Forward P/E
11.5×
-34.3%
Profit Margin
13.6%
78.1%
Gross Margin
76.6%
-26.4%
ROE
41.2%
Revenue Growth
4.9%
Earnings Growth
0.78
Beta
0.28
Price / Book
$8.2B
Market Cap
$277.0B
$73 – $147
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →